Patrick Reagan, MD
Internal Medicine · Rochester, NYNPI 1467686659
Payments from drug & device makers
Across 343 payments — averaging $27,431 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6.1M
- Genentech, Inc.$1M
- Seagen Inc.$791K
- Bristol Myers Squibb$487K
- Pfizer$383K
- Astrazeneca UK Limited$161K
- plus $406K from 6 others
Across 4 payments — averaging $1374.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$8,83093%
- Travel & lodging$3794%
- Food & beverage$2823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 232 | $6,147,842 |
| Genentech, Inc. | 41 | $1,033,123 |
| Seagen Inc. | 8 | $791,204 |
| Bristol Myers Squibb | 9 | $487,403 |
| Pfizer | 5 | $382,593 |
| Astrazeneca UK Limited | 12 | $160,623 |
| Modernatx, Inc. | 20 | $148,835 |
| Incyte Corporation | 8 | $148,291 |
| Morphosys AG | 5 | $108,755 |
| Genentech USA, Inc. | 1 | $74 |
| Astellas Pharma Global Development | 1 | $59 |
| Acera Surgical, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecartus$2,500
How this compares
$9,408,827 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 34 | $436,439 |
| ImbruvicaIbrutinib | 18 | $303,982 |
| CalquenceAcalabrutinib Maleate | 16 | $157,476 |
| Acyclovir | 39 | $490 |
| Prochlorperazine Maleate | 23 | $279 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $114 |
| Prednisone | 43 | $86 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rochester
- Angela BrancheRochester$7.9M
- Patrick ConnorsRochester$4M
- Richard DunneRochester$1.6M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.